Cited by 162Colorectal Cancer Treatments and StudiesCancer Mechanisms and TherapyProtein Kinase Regulation and GTPase Signaling

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells Is Mediated by Oxidative Stress

Open access

Kopetz, Scott, Lesslie, Donald P., Dallas, Nikolas A., Park, Serk I., Johnson, Marjorie, Parikh, Nila U., Kim, Michael P., Abbruzzese, James L., Ellis, Lee M., Chandra, Joya, Gallick, Gary E.·2009·Cancer Research

DOI 10.1158/0008-5472.can-08-2246PMC PMC2709758

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

Chemotherapeutic regimens for the treatment of colorectal cancer generally include oxaliplatin, although inherent and acquired resistance is common. One potential mediator of oxaliplatin sensitivity is the nonreceptor protein tyrosine kinase, Src, the activity of which correlates with disease stage and patient survival. Therefore, we investigated the effects of Src inhibition using the tyrosine kinase inhibitor dasatinib on oxaliplatin sensitivity. We show that oxaliplatin acutely activates Src and that combination treatment with dasatinib is synergistic in a cell-line dependent manner, with the level of Src activation correlating with extent of synergy in a panel of six cell lines. Intracellular reactive oxygen species (ROS) are generated after oxaliplatin treatment, and ROS potently activates Src. Pretreatment with antioxidants inhibits oxaliplatin-induced Src activation. In oxaliplatin-resistant cell lines, Src activity is constitutively increased. In a mouse model of colorectal liver metastases, treatment with oxaliplatin also results in chronic Src activation. The combination of dasatinib and oxaliplatin results in significantly smaller tumors compared with single-agent treatment, corresponding with reduced proliferation and angiogenesis. Therefore, we conclude that oxaliplatin activates Src through a ROS-dependent mechanism. Src inhibition increases oxaliplatin activity both in vitro and in vivo. These results suggest that Src inhibitors combined with oxaliplatin may have efficacy in metastatic colon cancer and may provide the first indication of a molecular phenotype that might be susceptible to such combinations. [Cancer Res 2009;69(9):3842–9]

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-08-2246

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
The resurgence of platinum-based cancer chemotherapy
Kèlland, L. R. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2167 · Cited by 4,733
Evaluation of the probe 2',7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress
LeBel, C. P., Ischiropoulos, H., & Bondy, S. C. (1992) · Chemical Research in Toxicology · doi:10.1021/tx00026a012 · Cited by 2,694
ROS stress in cancer cells and therapeutic implications
Pelicano, H., Carney, D. A., & Huang, P. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.01.004 · Cited by 2,031
Discovery of N -(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays
Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D. J., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,303
Angiostatin induces and sustains dormancy of human primary tumors in mice
O’Reilly, M. S., Holmgren, L., Chen, C., & Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0696-689 · Cited by 1,170
High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.
Godwin, A. K., Meister, A., O'Dwyer, P. J., Huang, C. S., Hamilton, T. C., & Anderson, M. E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.3070 · Cited by 926
Chronic Oxaliplatin Resistance Induces Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cell Lines
Yang, A. D., Fan, F., Camp, E. R., Buren, G. V., Liu, W., Somcio, R., Gray, M. J., Cheng, H. Y., Hoff, P. M., & Ellis, L. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0038 · Cited by 526
Self-citation
Controlling Tumor Growth by Modulating Endogenous Production of Reactive Oxygen Species
Laurent, A., Nicco, C., Chéreau, C., Goulvestre, C., Alexandre, J., Alvès, A., Lévy, E., Goldwasser, F., Panis, Y. H., Soubrane, O., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.948.65.3 · Cited by 516

Show all 46 references

Research works printed but not linked: 2

Eng C, Kopetz S, Morris J, et al. Phase II study of the novel oral Src-kinase inhibitor, AZD0530, in previously treated advanced colorectal cancer patients. Proceedings of the 98th Annual Meeting of the AACR; 2008. San Diego, CA. p. LB-76.
Kopetz S, Wolff RA, C E, et al. Phase IB study of Src inhibition with dasatinib in combination with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) and cetuximab in metastatic colorectal cancer. Proceedings of the 98th Annual Meeting of the AACR; 2008 Apr 12-16; San Diego, CA. p. LB-69.

Sorted by citations

Upsides and Downsides of Reactive Oxygen Species for Cancer: The Roles of Reactive Oxygen Species in Tumorigenesis, Prevention, and Therapy
Gupta, S. C., Hevia, D., Patchva, S., Park, B., Koh, W., & Aggarwal, B. B. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4414 · Cited by 759
Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
Frentzas, S., Simoneau, È., Bridgeman, V. L., Vermeulen, P., Foo, S., Kostaras, E., Nathan, M. R., Wotherspoon, A. C., Gao, Z., Shi, Y., et al. (2016) · Nature Medicine · doi:10.1038/nm.4197 · Cited by 456
Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation
Nassini, R., Gees, M., Harrison, S., Siena, G. D., Materazzi, S., Moretto, N., Failli, P., Preti, D., Marchetti, N., Cavazzini, A., et al. (2011) · Pain · doi:10.1016/j.pain.2011.02.051 · Cited by 326
Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
Mao, M., Tian, F., Mariadason, J. M., Tsao, C. C., Lemos, R., Dayyani, F., Gopal, Y. N. V., Jiang, Z.-Q., Wistuba, I. I., Tang, X. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1446 · Cited by 290
Self-citation
Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors
Araujo, J., & Logothetis, C. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.02.015 · Cited by 244
Regulation of Src Family Kinases in Human Cancers
Sen, B., & Johnson, F. M. (2011) · Journal of Signal Transduction · doi:10.1155/2011/865819 · Cited by 235
Targeted Delivery of Small Interfering RNA Using Reconstituted High-Density Lipoprotein Nanoparticles
Shahzad, M. M. K., Mangala, L. S., Han, H. D., Lü, C., Bottsford-Miller, J. N., Nishimura, M., Mora, E., Lee, J., Stone, R. L., Pecot, C. V., et al. (2011) · Neoplasia · doi:10.1593/neo.101372 · Cited by 221
Self-citation
SRC: A Century of Science Brought to the Clinic
Aleshin, A. A., & Finn, R. S. (2010) · Neoplasia · doi:10.1593/neo.10328 · Cited by 216
Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib
Broxterman, H. J., Gotink, K. J., & Verheul, H. M. W. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.07.001 · Cited by 209
The Role of Lysyl Oxidase in SRC-Dependent Proliferation and Metastasis of Colorectal Cancer
Baker, A., Cox, T. R., Bird, D., Lang, G., Murray, G. I., Sun, X., Southall, S. M., Wilson, J. R., & Erler, J. T. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq569 · Cited by 206
Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins
Minematsu, T., & Giacomini, K. M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0731 · Cited by 199
Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer
Espey, M. G., Chen, P., Chalmers, B. P., Drisko, J., Sun, A. Y., Levine, M., & Chen, Q. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.03.007 · Cited by 192
Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation
Ding, Z., Hui, B., Shi, Y., Zhou, J., Peng, Y., Gu, C., Yang, H., Shi, G., Ke, A., Wang, X., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0816 · Cited by 180
Cancer drug resistance: redox resetting renders a way
Liu, Y., Li, Q., Zhou, L., Xie, N., Nice, E. C., Zhang, H., Huang, C., & Lei, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.8600 · Cited by 182
Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer
Johnson, F. M., Bekele, B. N., Feng, L., Wistuba, I. I., Tang, X., Tran, H. T., Erasmus, J. J., Hwang, L.-L., Takebe, N., Blumenschein, G. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5474 · Cited by 167
Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells
Nautiyal, J., Kanwar, S. S., Yu, Y., & Majumdar, A. P. N. (2011) · Journal of Molecular Signaling · doi:10.1186/1750-2187-6-7 · Cited by 149
Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells
Poh, A. R., O’Donoghue, R. J. J., & Ernst, M. (2015) · Oncotarget · doi:10.18632/oncotarget.4199 · Cited by 147
Src: a potential target for the treatment of triple-negative breast cancer
Tryfonopoulos, D. J., Walsh, S., Collins, D. M., Flanagan, L., Quinn, C., Corkery, B., McDermott, E. W. M., Evoy, D., Pierce, A., O’Donovan, N., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq757 · Cited by 138
The Role of Src in Colon Cancer and Its Therapeutic Implications
Chen, J., Elfiky, A. A., Han, M., Chen, C., & Saif, M. W. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.10.003 · Cited by 129
Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in human pancreatic cancer cells
Li, X., Zhu, F., Jiang, J., Sun, C., Wang, X., Shen, M., Tian, R., Shi, C., Xu, M., Peng, F., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.11.026 · Cited by 116
Oxaliplatin-induced oxidative stress in nervous system-derived cellular models: Could it correlate with in vivo neuropathy?
Mannelli, L. D. C., Zanardelli, M., Failli, P., & Ghelardini, C. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.019 · Cited by 106
Targeting DNA damage and repair: Embracing the pharmacological era for successful cancer therapy
Aziz, K., Nowsheen, S., Pantelias, G. E., Iliakis, G. E., Gorgoulis, V. G., & Georgakilas, A. G. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.11.010 · Cited by 107
Combined Blockade of Src Kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediated Resistance of Inhibition of Pancreatic Tumor Growth
Liu, E., Nagaraj, N. S., Washington, M. K., & Merchant, N. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1670 · Cited by 95
The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress
Chen, W., Lian, W., Yuan, Y., & Li, M. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1824-6 · Cited by 90
Regulation of Src Family Kinases during Colorectal Cancer Development and Its Clinical Implications
Jin, W. (2020) · Cancers · doi:10.3390/cancers12051339 · Cited by 86
Antioxidants decrease the apoptotic effect of 5-Fu in colon cancer by regulating Src-dependent caspase-7 phosphorylation
Fu, Y., Yang, G., Zhu, F., Peng, C., Li, W., Li, H., Kim, H.-G., Bode, A. M., Dong, Z., & Dong, Z. (2014) · Cell Death and Disease · doi:10.1038/cddis.2013.509 · Cited by 90
The Src Family of Protein Tyrosine Kinases: A New and Promising Target for Colorectal Cancer Therapy
Lieu, C. H., & Kopetz, S. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.012 · Cited by 87
Self-citation
Novel dual Src/Abl inhibitors for hematologic and solid malignancies
Schenone, S., Brullo, C., Musumeci, F., & Botta, M. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.499898 · Cited by 83
Plasticity of Cancer Cell Invasion—Mechanisms and Implications for Therapy
Boekhorst, V. T., & Friedl, P. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.07.005 · Cited by 89
Orally Administrated Hydrogel Harnessing Intratumoral Microbiome and Microbiota-Related Immune Responses for Potentiated Colorectal Cancer Treatment
Li, L., He, S., Liao, B., Wang, M., Lin, H., Hu, B., Lan, X., Shu, Z., Zhang, C., Yu, M., et al. (2024) · Research · doi:10.34133/research.0364 · Cited by 79
Adjuvant Chemotherapy With FOLFOX for Primary Colorectal Cancer Is Associated With Increased Somatic Gene Mutations and Inferior Survival in Patients Undergoing Hepatectomy for Metachronous Liver Metastases
Andreou, A., Kopetz, S., Maru, D. M., Chen, S. S., Zimmitti, G., Brouquet, A., Shindoh, J., Curley, S. A., Garrett, C. R., Overman, M. J., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31826b4dcc · Cited by 79
Self-citation
The multiple and enigmatic roles of guanylyl cyclase C in intestinal homeostasis
Arshad, N., & Visweswariah, S. S. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.07.028 · Cited by 76
Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells
Chang, A., & Wang, M. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-267 · Cited by 66
Recent Insights into Mucinous Ovarian Carcinoma
Ricci, F., Affatato, R., Carrassa, L., & Damia, G. L. M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061569 · Cited by 71
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
Parseghian, C. M., Parikh, N. U., Wu, J. Y., Jiang, Z.-Q., Henderson, L., Tian, F., Pastor, B., Ychou, M., Raghav, K., Dasari, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3138 · Cited by 67
Self-citation
Role of c-Src in Carcinogenesis and Drug Resistance
Raji, L. M., Tetteh, A., & Amin, A. R. M. R. (2023) · Cancers · doi:10.3390/cancers16010032 · Cited by 67
Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer
Nam, H.-J., Im, S., Oh, D., Elvin, P., Kim, H., Yoon, Y.-K., Min, A., Song, S.-H., Han, S.-W., Kim, T.-Y., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0109 · Cited by 62
Pharmacological Ascorbate Suppresses Growth of Gastric Cancer Cells with GLUT1 Overexpression and Enhances the Efficacy of Oxaliplatin Through Redox Modulation
Lu, Y., Wu, Q.-N., Chen, D.-L., Chen, L.-Z., Wang, Z., Ren, C., Mo, H., Ya, C., Sheng, H., Wang, Y.-N., et al. (2018) · Theranostics · doi:10.7150/thno.21745 · Cited by 67
Gene Array and Fluorescence In situ Hybridization Biomarkers of Activity of Saracatinib (AZD0530), a Src Inhibitor, in a Preclinical Model of Colorectal Cancer
Arcaroli, J. J., Touban, B. M., Tan, A. C., Varella-Garcia, M., Powell, R. W., Eckhardt, S. G., Elvin, P., Gao, D., & Messersmith, W. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0066 · Cited by 64
Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer.
Sirvent, A., Bénistant, C., & Roche, S. (2012) · Europe PMC (PubMed Central) · Cited by 61
Src Inhibitors in Lung Cancer: Current Status and Future Directions
Rothschild, S. I., Gautschi, O. P., Haura, E. B., & Johnson, F. M. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.030 · Cited by 59
Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplatin
Ceppi, P., Papotti, M. G., Monica, V., Iacono, M. L., Saviozzi, S., Pautasso, M., Novello, S., Mussino, S., Bracco, E., Volante, M., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0151 · Cited by 58
Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways
Raju, U., Riesterer, O., Wang, Z., Molkentine, D. P., Molkentine, J. M., Johnson, F. M., Glisson, B. S., Milas, L., & Ang, K. K. (2012) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2012.08.010 · Cited by 56
YES1: A Novel Therapeutic Target and Biomarker in Cancer
Garmendia, I., Redín, E., Montuenga, L. M., & Calvo, A. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0958 · Cited by 53
Mucinous ovarian cancer: A therapeutic review
Xu, W., Rush, J., Rickett, K., & Coward, J. I. G. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.03.015 · Cited by 54
Novel N-Substituted Amino Acid Hydrazone-Isatin Derivatives: Synthesis, Antioxidant Activity, and Anticancer Activity in 2D and 3D Models In Vitro
Tumosienė, I., Jonuškienė, I., Kantminienė, K., Mickevičius, V., & Petrikaitė, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157799 · Cited by 53
Src drives the Warburg effect and therapy resistance by inactivating pyruvate dehydrogenase through tyrosine-289 phosphorylation
Jin, Y., Cai, Q., Shenoy, A. K., Lim, S., Zhang, Y., Charles, S., Tarrash, M., Fu, X., Kamarajugadda, S., Trevino, J. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7159 · Cited by 55
Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29.
Chen, J., Huang, X., Qiao, L., & Katsifis, A. G. (2011) · PubMed Central · doi:10.3978/j.issn.2078-6891.2010.028 · Cited by 49
Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer
Reddy, S. M., Kopetz, S., Morris, J. S., Parikh, N. U., Qiao, W., Overman, M. J., Fogelman, D. R., Shureiqi, I., Jacob, C., Malik, Z., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0257-z · Cited by 55
Self-citation
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium
Sharma, M. R., Wroblewski, K., Polite, B. N., Knost, J. A., Wallace, J. A., Modi, S., Sleckman, B. G., Taber, D., Vokes, E. E., Stadler, W. M., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9681-x · Cited by 49
The molecular rationale of Src inhibition in colorectal carcinomas
Gargalionis, A. N., Karamouzis, M. V., & Papavassiliou, A. G. (2014) · International Journal of Cancer · doi:10.1002/ijc.28299 · Cited by 47
Oxidative damage to guanine nucleosides following combination chemotherapy with 5-fluorouracil and oxaliplatin
Afzal, S., Jensen, S. A., Sørensen, J. B., Henriksen, T., Weimann, A., & Poulsen, H. E. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1700-2 · Cited by 47
Targeting Src in Mucinous Ovarian Carcinoma
Matsuo, K., Nishimura, M., Bottsford-Miller, J. N., Huang, J., Komurov, K., Armaiz-Peña, G. N., Shahzad, M. M. K., Stone, R. L., Roh, J., Sanguino, A. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3176 · Cited by 45
Self-citation
Long-Chain Fatty Acid Analogues Suppress Breast Tumorigenesis and Progression
Gluschnaider, U., Hertz, R., Ohayon, S., Smeir, E., Smets, M., Pikarsky, E., & Bar‐Tana, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0385 · Cited by 47
The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia
Overman, M. J., Ferrarotto, R., Raghav, K. P. S., George, B., Qiao, W., Machado, K. K., Saltz, L. B., Mazard, T., Vauthey, J., Hoff, P. M., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx288 · Cited by 43
Self-citation
The function of miR-200 family in oxidative stress response evoked in cancer chemotherapy and radiotherapy
Kozak, J., Jonak, K. E., & Maciejewski, R. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110037 · Cited by 42
Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells
Chen, B., Xu, X., Luo, J., Wang, H., & Zhou, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129663 · Cited by 42
Combined Inhibition of IGF-1R/IR and Src Family Kinases Enhances Antitumor Effects in Prostate Cancer by Decreasing Activated Survival Pathways
Dayyani, F., Parikh, N. U., Varkaris, A. S., Song, J. H., Moorthy, S., Chatterji, T., Maity, S. N., Wolfe, A. R., Carboni, J. M., Gottardis, M. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051189 · Cited by 40
Self-citation
Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
Liu, T., Hu, W., Dalton, H. J., Choi, H. J., Huang, J., Kang, Y., Pradeep, S., Miyake, T. M., Song, J. H., Wen, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1305 · Cited by 40
Self-citation
Cigarette smoke extract exposure induces EGFR-TKI resistance in EGFR-mutated NSCLC via mediating Src activation and EMT
Li, D., Zhang, L., Zhou, J., & Chen, H. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.12.007 · Cited by 39
Cancer therapy and cachexia
Thakir, T. M., Wang, A. R., Decker-Farrell, A. R., Ferrer, M., Guin, R. N., Kleeman, S. O., Levett, L. M., Zhao, X., & Janowitz, T. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191934 · Cited by 42
Multiplex Profiling of Biomarker and Drug Uptake in Single Cells Using Microfluidic Flow Cytometry and Mass Spectrometry
Zhang, X., Wei, X., Wu, C., Men, X., Wang, J., Bai, J., Sun, X., Wang, Y., Yang, T., Lim, C. T., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c12803 · Cited by 37
Dasatinib Is Preclinically Active against Src-Overexpressing Human Transitional Cell Carcinoma of the Urothelium with Activated Src Signaling
Levitt, J. M., Yamashita, H., Jian, W., Lerner, S. P., & Sonpavde, G. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0096 · Cited by 37
Sublethal concentrations of the platinum(II) complex [Pt(O,O′‐acac)(γ‐acac)(DMS)] alter the motility and induce anoikis in MCF‐7 cells
Muscella, A., Calabriso, N., Vetrugno, C., Urso, L., Fanizzi, F. P., Pascali, S. A. D., & Marsigliante, S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00782.x · Cited by 37
Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model
Scott, A. J., Song, E., Bagby, S. M., Purkey, A., McCarter, M. D., Gajdos, C., Quackenbush, K. S., Cross, B. R., Pitts, T. M., Tan, A. C., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187173 · Cited by 36
The long-term impact of oxaliplatin chemotherapy on rodent cognition and peripheral neuropathy
Fardell, J. E., Vardy, J. L., Monds, L. A., & Johnston, I. N. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.04.038 · Cited by 35
pH-responsive nanoprodrugs combining a Src inhibitor and chemotherapy to potentiate antitumor immunity via pyroptosis in head and neck cancer
Zhu, S., Ye, M., Ma, X., Wu, Z., Wan, S., Yang, S., Li, H., Xu, Z., & Sun, Z. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.10.051 · Cited by 35
Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src
Perez, M., Lucena-Cacace, A., Marín-Gómez, L. M., Padillo-Ruiz, J., Robles-Frias, M. J., Saez, C., Garcia-Carbonero, R., & Carnero, A. (2016) · Oncotarget · doi:10.18632/oncotarget.8880 · Cited by 34
Analysis of SRC Oncogenic Signaling in Colorectal Cancer by Stable Isotope Labeling with Heavy Amino Acids in Mouse Xenografts
Sirvent, A., Vigy, O., Orsetti, B., Urbach, S., & Roche, S. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.018168 · Cited by 33
SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer
Gururajan, M., Cavassani, K. A., Sievert, M. F., Duan, P., Lichterman, J. N., Huang, J.-M., Smith, B., You, S., Nandana, S., Chu, G. C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6398 · Cited by 33
Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling
Xiao, J., Xu, M., Hou, T., Huang, Y., Yang, C., & LI, J. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3784 · Cited by 35
Brain Metastases from Colorectal Cancer: Microenvironment and Molecular Mechanisms
Zang, Y.-W., Gu, X., Xiang, J., & Chen, Z. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131215784 · Cited by 36
Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer
Lee, M. S., & Kopetz, S. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.05.006 · Cited by 33
Self-citation
No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis
Zhou, S., Huang, Y., Wei, Y., Jiang, Z.-M., Zhang, Y.-D., Yang, Q., & Xie, D.-R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050925 · Cited by 31
The signalling axis mediating neuronal apoptosis in response to [Pt(O,O′-acac)(γ-acac)(DMS)]
Muscella, A., Calabriso, N., Vetrugno, C., Fanizzi, F. P., Pascali, S. A. D., & Marsigliante, S. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.03.007 · Cited by 31
Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival
Ptashkin, R. N., Pagan, C. A., Yaeger, R. D., Middha, S., Shia, J., O’Rourke, K. P., Berger, M. F., Wang, L., Cimera, R., Wang, J., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0352 · Cited by 31
Anti-proliferative potential of phytochemical fractions isolated from Simarouba glauca DC leaf
Jose, A., Kannan, E., & Madhunapantula, S. V. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e03836 · Cited by 30
Src Family Tyrosine Kinases in Intestinal Homeostasis, Regeneration and Tumorigenesis
Sirvent, A., Mevizou, R., Naim, D., Lafitte, M., & Roche, S. (2020) · Cancers · doi:10.3390/cancers12082014 · Cited by 31
Anti-GPR56 monoclonal antibody potentiates GPR56-mediated Src-Fak signaling to modulate cell adhesion
Chatterjee, T., Zhang, S., Posey, T. A., Jacob, J., Wu, L., Yu, W., Francisco, L. E., Liu, Q. J., & Carmon, K. S. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100261 · Cited by 28
Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and Casein Kinase II inhibition as a potential treatment option
Willems, S. M., Schrage, Y. M., Bruijn, I. H. B., Szuhai, K., Hogendoorn, P. C. W., & Bovée, J. V. M. G. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-257 · Cited by 30
Src-family tyrosine kinases as therapeutic targets in advanced cancer
Gelman, I. H. (2011) · Frontiers in Bioscience · doi:10.2741/e287 · Cited by 28
Pathways of metastasis suppression in bladder cancer
Said, N. A., & Theodorescu, D. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9197-4 · Cited by 29
A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer
Heijink, D. M., Fehrmann, R. S. N., de Vries, E. G. E., Koornstra, J. J., Oosterhuis, D., van der Zee, A. G. J., KLEIBEUKER, J. H., & de Jong, S. (2011) · Oncogene · doi:10.1038/onc.2010.578 · Cited by 28
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer
Strickler, J. H., McCall, S. J., Nixon, A. B., Brady, J. C., Pang, H., Rushing, C. N., Cohn, A. L., Starodub, A., Arrowood, C., Haley, S. T., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0042-9 · Cited by 27
Synergism from the combination of oxaliplatin with selected phytochemicals in human ovarian cancer cell lines.
Yunos, N. M., Beale, P. J., Yu, J. Q., & Huq, F. (2011) · PubMed · Cited by 26
The Src/PI3K/Akt signal pathway may play a key role in decreased drug efficacy in obesity‐associated cancer
Chen, J. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22572 · Cited by 26
Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells
Duong, H., Yi, Y. W., Kang, H. J., Bae, I., Jang, Y., Kwak, S., & Seong, Y. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2357 · Cited by 26
Upregulation of Tyrosine Kinase FYN in Human Thyroid Carcinoma: Role in Modulating Tumor Cell Proliferation, Invasion, and Migration
Zheng, J. J., Li, H., Xu, D., & Zhu, H. (2017) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2017.2218 · Cited by 27
Src Family Kinase Inhibitor Saracatinib (AZD0530) Impairs Oxaliplatin Uptake in Colorectal Cancer Cells and Blocks Organic Cation Transporters
Morrow, C. J., Ghattas, M. A., Smith, C. G., Bönisch, H., Bryce, R. A., Hickinson, D. M., Green, T. P., & Dive, C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0694 · Cited by 26
Phase I study of dasatinib (BMS‐354825) in Japanese patients with solid tumors
Takahashi, S., Miyazaki, M., Okamoto, I., Ito, Y., Ueda, K., Seriu, T., Nakagawa, K., & Hatake, K. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02041.x · Cited by 24
The Tyrosine Kinase Inhibitor Dasatinib Induces a Marked Adipogenic Differentiation of Human Multipotent Mesenchymal Stromal Cells
Borriello, A., Caldarelli, I., Basile, M. A., Bencivenga, D., Tramontano, A., Perrotta, S., Ragione, F. D., & Oliva, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028555 · Cited by 24
Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells
Shi, M., Lou, B.-X., Ji, J., Shi, H., Zhou, C., Yu, Y., Liu, B., Zhu, Z., & Zhang, J. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2166-1 · Cited by 21
Prognostic relevance of Src activation in stage II-III colon cancer
Martínez-Pérez, J., Lopez-Calderero, I., Saez, C., Benavent, M., Limon, M. L., Gonzalez-Exposito, R., Soldevilla, B., Riesco-Martínez, M. C., Salamanca, J., Carnero, A., et al. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.05.025 · Cited by 20
Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer
Iyer, K. K., van Erp, N. P., Tauriello, D. V. F., Verheul, H. M. W., & Poel, D. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102466 · Cited by 20
Src inhibitor dasatinib sensitized gastric cancer cells to cisplatin
Wang, H.-Z., Lu, Y.-D., Wang, M.-L., Shen, A.-L., Wu, Y.-L., Xu, X., & Li, Y.-X. (2022) · Medical Oncology · doi:10.1007/s12032-022-01879-6 · Cited by 16
High hepatic expression of PDK4 improves survival upon multimodal treatment of colorectal liver metastases
Strowitzki, M. J., Radhakrishnan, P., Pavicevic, S., Scheer, J., Kimmer, G., Ritter, A. S., Tuffs, C., Volz, C., Vondran, F. W. R., Harnoss, J. M., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0406-9 · Cited by 20
BRAF V600E and SRC mutations as molecular markers for predicting prognosis and conversion surgery in Stage IV colorectal cancer
Shimada, Y., Muneoka, Y., Nagahashi, M., Ichikawa, H., Tajima, Y., Hirose, Y., Ando, T., Nakano, M., Sakata, J., Kameyama, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39328-6 · Cited by 19
Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines
Nannizzi, S., Veal, G. J., Giovannetti, E., Mey, V., Ricciardi, S., Ottley, C. J., Tacca, M. D., & Danesi, R. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1195-2 · Cited by 19
Dasatinib reduces 5-Fu-triggered apoptosis in colon carcinoma by directly modulating Src-dependent caspase-9 phosphorylation
Fu, Y., Yang, G., Xue, P., Guo, L., Yin, Y., Ye, Z., Peng, S., Qin, Y., Duan, Q., & Zhu, F. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0062-5 · Cited by 19
Changes in the levels of thioredoxin and indoleamine-2,3-dioxygenase activity in plasma of patients with colorectal cancer treated with chemotherapy
Cavia-Sáiz, M., Múñiz, P., Santiago, R. D., Herreros‐Villanueva, M., Girón, C. G., López, A. S., & Corral, M. J. C.-D. (2012) · Biochemistry and Cell Biology · doi:10.1139/o11-077 · Cited by 18

Authors: Kopetz, S., Lesslie, D. P., Dallas, N. A., Park, S. I., Johnson, M., Parikh, N. U., Kim, M. P., Abbruzzese, J. L., Ellis, L. M., Chandra, J., & Gallick, G. E.
Affiliations: 1Cancer Biology, Departments of
2Gastrointestinal Medical Oncology,
The University of Texas MD Anderson Cancer Center (US)
ORCID: Kopetz, Scott
Park, Serk I.
Parikh, Nila U.
Kim, Michael P.
Abbruzzese, James L.
Ellis, Lee M.
Chandra, Joya
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2009-04-30
Volume: 69
Issue: 9
Pages: 3842-3849
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-08-2246
PMC: PMC2709758
OpenAlex: W2092343827
Cited by: 160
References: 46
Citations by year: 2026: 2 · 2025: 4 · 2024: 6 · 2023: 9 · 2022: 9 · 2021: 7 · 2020: 7 · 2019: 4 · 2018: 6 · 2017: 7 · 2016: 11 · 2015: 9 · 2014: 8 · 2013: 12 · 2012: 16
FWCI: 9.84
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (5p20ca101936-05, KL2TR000370, CA088084, CA101936)
National Cancer Institute (U54CA090810, K23CA136980, T-32 CA 09599, P20-CA101936, L30 CA124227, T32CA009599, K12CA088084)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords: dasatinib, oxaliplatin, Src family kinases, colorectal cancer, combination chemotherapy, oxidative stress, reactive oxygen species, drug synergy, chemoresistance, antioxidants, colorectal liver metastases, angiogenesis, cell proliferation
MeSH terms: Dasatinib, Oxaliplatin, Animals, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Drug Synergism, Humans, Liver Neoplasms, Experimental, Male, Mice, Nude, Neovascularization, Pathologic, Organoplatinum Compounds, Pyrimidines, Random Allocation, Thiazoles, Down-Regulation, Apoptosis, Reactive Oxygen Species, Oxidative Stress, src-Family Kinases, HT29 Cells, Vascular Endothelial Growth Factor A, HCT116 Cells, Protein Kinase Inhibitors, Cell Growth Processes, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells Is Mediated by Oxidative Stress

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks